Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

SCCA physicians honored as "Top Doctors" for providing outstanding cancer care

Seattle Cancer Care Alliance doctors were recently honored by a judging panel of their peers for providing outstanding cancer care.

24 Jul 2013

Genentech announces that Phase III CLL11 study meets primary endpoint

Genentech, a member of the Roche Group, today announced positive results from the Phase III CLL11 study. At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan (rituximab) plus chlorambucil.

24 Jul 2013

Breast cancer pilot study: Patients benefit from treatments guided by molecular profiling

The Side-Out Foundation's breast cancer pilot study, led by the Translational Genomics Research Institute, Translational Drug Development and Scottsdale Healthcare, has shown that cancer patients do better when their treatment is guided by molecular profiling.

18 Jul 2013

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.

18 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

Companion test also approved to identify appropriate patients The U.S. Food and Drug Administration today approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Lung cancer is the leading cause of cancer-related death among men and women.

16 Jul 2013

Childhood cancer survivors can still get pregnant despite increased risk of infertility

Although women who survived childhood cancer face an increased risk of infertility, nearly two-thirds of those who tried unsuccessfully to become pregnant for at least a year eventually conceived, according to clinical researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Brigham and Women's Hospital. This is comparable to the rate of eventual pregnancy among all clinically infertile women.

15 Jul 2013

UNMC conducts clinical trial on Leukine to test unique immune therapy in people with Parkinson's

The Nebraska Neuroscience Alliance at the University of Nebraska Medical Center, is embarking on a translational clinical trial using Leukine, a drug used to boost the immune system in cancer patients, to test a unique immune therapy in people with Parkinson's disease.

11 Jul 2013

Advanced genetics technologies may help predict patient outcomes in people with ALL

New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic leukemia (ALL).

10 Jul 2013

USMD Holdings extends patient-centric medical care to Alaska

USMD Holdings, Inc. announced today it is extending high-quality, patient-centric medical care to the 49th state by partnering with the Alaska Institute of Surgical & Medical Specialties in Anchorage.

8 Jul 2013

Bayer starts enrollment in BAY94-9027 Phase II/III trial for hemophilia A in children

Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A in children.

8 Jul 2013

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Baxter International Inc. today announced data featuring ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], a leading recombinant treatment available worldwide, during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands.

From Baxter International Inc. 5 Jul 2013

Research shows over 50% of tumors have mutations in p53

Researchers of the Cancer Metabolism group at the Bellvitge Biomedical Research Institute (IDIBELL), Catalan Oncology Institute (ICO) and the Division of Hematology-Oncology of the University of Cincinnati, led by George Thomas, have discovered a role for ribosomal 5S RNA in the formation of a complex that regulates the stability of p53.

4 Jul 2013

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for obinutuzumab (GA101) and granted Priority Review for GA101 in the treatment of chronic lymphocytic leukemia, one of the most common forms of blood cancer, based on final Stage 1 data from the pivotal CLL11 trial.

3 Jul 2013

VIZZIA Technologies' clinical workflow optimization solution installed at FCS Tampa Cancer Center

VIZZIA Technologies, a leading provider of process and technology solutions, announced today that its clinical workflow optimization solution was recently installed at Florida Cancer Specialists & Research Institute's Tampa Cancer Center location.

2 Jul 2013

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemophilia and rare bleeding disorders.

2 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Case Comprehensive Cancer Center secures "outstanding" rating from NCI

The Case Comprehensive Cancer Center (CCCC) again demonstrated the compelling power of partnership in securing an overall rating of "outstanding" and a five-year renewal of its grant from the National Cancer Institute (NCI).

28 Jun 2013

Researchers study possible alternative medications to treat cancer-related pain

Researchers at the Brain and Spine Institute at John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, are studying a possible alternative to side effect-ridden opioid-based medications to treat cancer-related pain.

27 Jun 2013

Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

Ambit Biosciences Corporation announced today data from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were featured in multiple presentations at the 18th Congress of the European Hematology Association in Stockholm, Sweden.

27 Jun 2013

Hematology News and Research

Further Reading

SCCA physicians honored as "Top Doctors" for providing outstanding cancer care

Genentech announces that Phase III CLL11 study meets primary endpoint

Breast cancer pilot study: Patients benefit from treatments guided by molecular profiling

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

Childhood cancer survivors can still get pregnant despite increased risk of infertility

UNMC conducts clinical trial on Leukine to test unique immune therapy in people with Parkinson's

Advanced genetics technologies may help predict patient outcomes in people with ALL

USMD Holdings extends patient-centric medical care to Alaska

Bayer starts enrollment in BAY94-9027 Phase II/III trial for hemophilia A in children

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Research shows over 50% of tumors have mutations in p53

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

VIZZIA Technologies' clinical workflow optimization solution installed at FCS Tampa Cancer Center

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Case Comprehensive Cancer Center secures "outstanding" rating from NCI

Researchers study possible alternative medications to treat cancer-related pain

Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo